Form 4 for ONC BeOne Medicines Ltd.
Accepted 2023-06-20 00:00:00 ET · period of report 2023-06-15 · accession 0001651308-23-000095 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-20 | 2023-06-15 | ONC | Glazer Donald W. | Dir | A - Grant | $0.00 | +12.9K | 2.78M | +0.5% | $0 |
| D | 2023-06-20 | 2023-06-15 | ONC | Glazer Donald W. | Dir | A - Grant | $0.00 | +27.0K | 27.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2023-06-15 | A | A | 12,922 | $0.00 | 2,784,143 | D | — | — | (F1) Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. |
| 2 | Derivative | Share Option (Right to Buy) | 2023-06-15 | A | A | 26,975 | $0.00 | 26,975 | D | $16.41 · — to 2033-06-14 | 26,975 Ordinary Shares | (F2) The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. (F3) The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. |